CDNA · CareDx, Inc.
Price & Indicators
Up next
Metrics snapshot
Useful current figures from the complete screener profile.
AI Brief
Q2 FY26 earnings call · Jul 30, 2026TL;DR. CareDx reported 52% Q2 revenue growth to $132 million and raised 2026 revenue guidance to $490–$500 million and adjusted EBITDA guidance to $66–$78 million, driven by Testing Services growth, the closing of the Lab Products divestiture and Naveris (NAVDX) acquisition, and finalized Medicare coverage for AlloSure and AlloMap.
- + 2026 revenue guidance raised to $490–$500 million and adjusted EBITDA guidance raised to $66–$78 million.
- + CMS finalized Medicare coverage policy for AlloSure and AlloMap, with a pathway for future HistoMap coverage.
- − Non-GAAP gross margin guidance of 71%–73% is below the 74% reported in Q2.
- − Specialty oncology ASP is guided at only $770–$795 per test in Q3/Q4, well below the $1,455–$1,465 transplant ASP.
AI-generated from the earnings call and 8-K · may contain errors · not investment advice
Equibles Rating
blended score · not investment adviceBlended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Guidance & track record
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders BuyIllustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
Earlier KPI extraction records exist, but do not meet the current evidence-completeness requirements. No current verified series is available. Earlier figures remain withheld until revalidated; this is not evidence that the company reports no KPIs.
Versus peers
Diagnostics & Research — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
CDNA
this stock
CareDx, Inc.
|
$3.31B | +239.8% | +18.9% | 30.9 | 12.2% |
|
TMO
Thermo Fisher Scientific Inc.
|
$249.58B | +17.3% | +14.5% | 36.3 | 1.4% |
|
DHR
Danaher Corp /De/
|
$155.42B | -1.2% | +8.5% | 39.2 | 1.2% |
|
NTRA
Natera, Inc.
|
$59.47B | +80.9% | -2.8% | — | 3.3% |
|
A
Agilent Technologies, Inc.
|
$48.90B | +26.6% | +6.4% | 34.2 | 1.8% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionPerformance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| CDNA | +13.3% | +27.8% | +257.3% | +27.8% | +239.8% |
| SPY | -1.2% | -0.4% | +13.1% | -0.4% | +12.1% |
| vs SPY | +14.5% | +28.1% | +244.2% | +28.1% | +227.7% |
Capital returns
Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.